Patent ID: 9102736
Filing Date: 2015-08-11
Classification: A61K,A61P,C07K

Abstract:
1. A cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain, wherein said first domain is deimmunized and comprises a CDR-H1 region comprising the amino acid sequence set forth in SEQ ID NO: 88, a CDR-H2 region comprising the amino acid sequence set forth in SEQ ID NO: 90 or SEQ ID NO: 92 and a CDR-H3 region, said CDR-H3 region comprising the amino acid sequence set forth in SEQ ID NO: 96, 108, 119, 120, 121, 122, 123, 124, 125, 126, or 127; wherein said first domain further comprises in its framework H1 the sequence VKK and wherein the transition sequence between framework H1 and CDR-H1 region comprises the amino acid sequence Ala-Ser-Gly-Tyr-Thr-Phe (ASGYTF; SEQ ID NO: 233); wherein said construct comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 98 or SEQ ID NO: 100, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 102, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 104; and wherein said Ig-derived second binding domain comprises an antigen-interaction site with a specificity for a molecule selected from the group consisting of EpCAM, CCR5, CD19, HER-2, HER-2 neu, HER-3, HER-4, EGFR, PSMA, CEA, mucin 1 (MUC1), MUC2, MUC3, MUC4, MUC5